
Anna-Maria Hoffmann-Vold
- Post doc; MD, PhD
Publications 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
Lancet Respir Med, 9 (1), 96-106
DOI 10.1016/S2213-2600(20)30330-1, PubMed 33412120
Publications 2020
The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients
Expert Rev Clin Immunol, 16 (11), 1065-1074
DOI 10.1080/1744666X.2021.1836962, PubMed 33076716
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Eur Respir J, 55 (5)
DOI 10.1183/13993003.02026-2019, PubMed 32079645
ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
BMJ Open Respir Res, 7 (1)
DOI 10.1136/bmjresp-2020-000598, PubMed 32576559
Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial
PLoS One, 15 (5), e0232739
DOI 10.1371/journal.pone.0232739, PubMed 32437393
Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort
Rheumatology (Oxford), 59 (10), 2920-2929
DOI 10.1093/rheumatology/keaa026, PubMed 32097470
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
Ann Rheum Dis, 80 (2), 219-227
DOI 10.1136/annrheumdis-2020-217455, PubMed 32988845
The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease
Respir Res, 21 (1), 197
DOI 10.1186/s12931-020-01459-0, PubMed 32703199
The potential of fecal microbiota transplantation in systemic sclerosis
Expert Rev Clin Immunol, 16 (2), 117-118
DOI 10.1080/1744666X.2019.1707665, PubMed 31858856
Circulating biomarkers of systemic sclerosis - interstitial lung disease
J. Scleroderma Relat. Disord., 5 (2_SUPPL 2_), 2397198319894851-47
European consensus statements for interstitial lung disease in systemic sclerosis Reply
Lancet Rheumatol., 2 (6), E319-E320
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Lancet Rheumatol., 2 (2), E71-E83
Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis
Curr Opin Rheumatol, 32 (6), 497-504
DOI 10.1016/s2213-2600(20)30318-0., PubMed 32890027
Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series
J. Scleroderma Relat. Disord., 5 (3), 2397198320916082-NP11
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey
Adv. Ther.
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
Ann Rheum Dis, 80 (2), 143-150
DOI 10.1136/annrheumdis-2020-217230, PubMed 33037004
Publications 2019
Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease
Expert Rev Clin Immunol, 15 (10), 1009-1017
DOI 10.1080/1744666X.2020.1668269, PubMed 31566449
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Ann Rheum Dis, 78 (7), 979-987
DOI 10.1136/annrheumdis-2018-214816, PubMed 30967395
Reply
Arthritis Rheumatol, 71 (7), 1204-1206
DOI 10.1002/art.40908, PubMed 31082000
Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
Arthritis Rheumatol, 71 (6), 972-982
DOI 10.1002/art.40815, PubMed 30624031
Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides
Rheumatology (Oxford), 58 (2), 313-320
DOI 10.1093/rheumatology/key285, PubMed 30281089
Reply
Arthritis Rheumatol, 71 (4), 655-656
DOI 10.1002/art.40816, PubMed 30663863
Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
RMD Open, 5 (1), e000826
DOI 10.1136/rmdopen-2018-000826, PubMed 30997150
Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort
Am J Respir Crit Care Med, 200 (10), 1258-1266
DOI 10.1164/rccm.201903-0486OC, PubMed 31310156
Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches
J. Scleroderma Relat. Disord., 2397198319891282
Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease
EBioMedicine, 50, 379-386
DOI 10.1016/j.ebiom.2019.10.050, PubMed 31732480
New ways in the treatment of SSc-ILD: what makes sense?
Pneumologe, 16 (5), 303-304
[New ways in the treatment of SSc-ILD: what makes sense?]
Z Rheumatol, 78 (9), 863-864
DOI 10.1007/s00393-019-00704-2, PubMed 31485729
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nat Commun, 10 (1), 4955
DOI 10.1038/s41467-019-12760-y, PubMed 31672989
Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications
ACR Open Rheumatol, 1 (4), 258-266
DOI 10.1002/acr2.1037, PubMed 31777802
Gastrointestinal tract microbiota modifications in systemic sclerosis
Eur J Rheumatol, 7 (Suppl 3), S228-S236
DOI 10.5152/eurjrheum.2019.19103, PubMed 31922474
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
J Rheumatol, 46 (10), 1316-1325
DOI 10.3899/jrheum.180441, PubMed 30770517
Publications 2018
Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort
Rheumatology (Oxford), 57 (3), 480-487
DOI 10.1093/rheumatology/kex435, PubMed 29237073
CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Arthritis Rheumatol, 70 (10), 1644-1653
DOI 10.1002/art.40534, PubMed 29687634
CCL21 as a potential biomarker for pulmonary arterial hypertension in systemic sclerosis
Arthritis Rheumatol (in press)
DOI 10.1002/art.40740, PubMed 30281215
Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis
PLoS One, 13 (11), e0206545
DOI 10.1371/journal.pone.0206545, PubMed 30457999
Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis
J Am Coll Cardiol, 72 (15), 1804-1813
DOI 10.1016/j.jacc.2018.07.068, PubMed 30286924
Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model
Ann Rheum Dis, 77 (9), 1326-1332
DOI 10.1136/annrheumdis-2018-213201, PubMed 29875097
Publications 2017
Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis
Arthritis Rheumatol, 69 (11), 2209-2221
DOI 10.1002/art.40229, PubMed 28805015
An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis
J Rheumatol, 44 (10), 1453-1457
DOI 10.3899/jrheum.161369, PubMed 28668810
Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort
J Rheumatol, 44 (4), 459-465
DOI 10.3899/jrheum.160867, PubMed 28089974
Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts
BMJ Open Gastroenterol, 4 (1), e000134
DOI 10.1136/bmjgast-2017-000134, PubMed 28761687
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II
Arthritis Rheumatol, 69 (7), 1451-1460
DOI 10.1002/art.40114, PubMed 28376288
Publications 2016
OX40L blockade protects against inflammation-driven fibrosis
Proc Natl Acad Sci U S A, 113 (27), E3901-10
DOI 10.1073/pnas.1523512113, PubMed 27298374
High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis
Chest, 150 (2), 299-306
DOI 10.1016/j.chest.2016.03.004, PubMed 26997242
Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis
Curr Opin Rheumatol, 28 (6), 613-8
DOI 10.1097/BOR.0000000000000323, PubMed 27387267
Publications 2015
Dr. Hoffmann-Vold replies
J Rheumatol, 42 (12), 2513
DOI 10.3899/jrheum.150886, PubMed 26628710
Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis
Arthritis Rheumatol, 67 (8), 2205-12
DOI 10.1002/art.39166, PubMed 25916462
Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study
Arthritis Res Ther, 17, 231
DOI 10.1186/s13075-015-0756-5, PubMed 26315510
Publications 2014
Dysfunctional arteriovenous anastomoses in hands of systemic sclerosis patients with digital ulcers
Clin Exp Rheumatol, 32 (6 Suppl 86), S-53-9
PubMed 24847906
Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease
J Rheumatol, 42 (1), 60-3
DOI 10.3899/jrheum.140047, PubMed 25274890
Publications 2013
Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis
J Rheumatol, 40 (7), 1127-33
DOI 10.3899/jrheum.121390, PubMed 23637316
Publications 2012
Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study
Ann Rheum Dis, 72 (4), 602-7
DOI 10.1136/annrheumdis-2012-201888, PubMed 22896740
A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis
Arthritis Res Ther, 14 (2), R85
DOI 10.1186/ar3809, PubMed 22531499
Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility
Ann Rheum Dis, 72 (7), 1233-8
DOI 10.1136/annrheumdis-2012-202357, PubMed 23172754
Prevalence of systemic sclerosis in south-east Norway
Rheumatology (Oxford), 51 (9), 1600-5
DOI 10.1093/rheumatology/kes076, PubMed 22539477
Publications 2011
Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population
Rheumatology (Oxford), 50 (11), 1976-81
DOI 10.1093/rheumatology/ker259, PubMed 21875883
Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis
Ann Rheum Dis, 70 (11), 2050-2
DOI 10.1136/ard.2010.148874, PubMed 21571730
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy
PLoS Genet, 7 (7), e1002178
DOI 10.1371/journal.pgen.1002178, PubMed 21779181
Publications 2010
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus
Nat Genet, 42 (5), 426-9
DOI 10.1038/ng.565, PubMed 20383147
Publications 2006
Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study
Arthritis Rheum, 54 (11), 3573-82
DOI 10.1002/art.22181, PubMed 17075863